Vivus Gets FDA Approval For Evamist Estradiol Spray
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval triggers $140 million payment from KV Pharmaceutical, which licensed the product in March.
You may also be interested in...
KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.
KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.
Columbia Expands Prochieve's Reach Beyond Infertility Market With Ascend License Agreement
Ascend’s 100 reps will detail the progesterone gel to over 14,000 women’s health physicians.